Meet Von der Leyen's husband

Heiko

Heiko has a net worth of £2.6 million and is the Medical Director of Orgenesis, which receives grants from the EU.

The largest shareholders of Orgenesis include Vanguard Group Inc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, VEXMX - Vanguard Extended Market Index Fund Investor Shares, Geode Capital Management, Llc, FSMAX - Fidelity Extended Market Index Fund, BlackRock Inc.,…

‘Orgenesis is a global biotech company that has been committed to unlocking the potential of cell and gene therapies (CGTs) since 2012 as well as a paradigm-shifting decentralized approach to processing since 2020. This new model allows Orgenesis to bring academia, hospitals, and industry together to make these essential therapies a reality sooner rather than later. Orgenesis is focusing on advancing its CGTs toward eventual commercialization, while partnering with key industry stakeholders to provide a rapid, globally harmonized pathway for these therapies to reach and treat a larger numbers of patients more cost effectively and with better outcomes through great science and decentralized production.’

Orgenesis has labs in Israel and it’s CEO ‘Ms. Caplan has a M.Sc. in biomedical engineering from Tel Aviv University specializing in signal processing; management for engineers from Tel Aviv University specializing in business development; and a B.Sc. in mechanical engineering from the Technion-Israel Institute of Technology specialized in software and cad systems.’ In 2023 she spoke at the Jewish Women’s Organisations of Maryland on Women in Israeli High-tech noting that Israelis have a more military style of leadership.

A question by Rosa D'Amato submitted to the European Parliament ‘Heiko von der Leyen, a doctor and scientific director of the US biotech company Orgenesis, which specialises in cell and gene therapies and is a frontrunner in the development of RNA COVID vaccines, is involved in the foundation established by the University of Padua on 8 June 2022 to manage research into RNA gene therapy and pharmaceuticals. This project is being financed under Italy’s National Recovery and Resilience Plan through the EUR 320 million paid to the Italian Ministry of Universities.

The Ordinary Assembly of the members of the foundation, called the ‘National Centre for Research and Development of gene therapy and pharmaceuticals using RNA technology’, at which the representatives of its governing bodies were elected, took place in Padua on 30 September 2022.

The research programme is being developed around a structure consisting of a hub – the University of Padua – and spokes, consisting of 49 bodies that include the universities of Siena, Modena, Rome and Milan, the Italian Institute of Technology, the Bambin Gesù Hospital in Rome and three private-sector companies. Von der Leyen represents Orgenesis, which is one of the project founders and will receive EUR 200 000 in contributions each year[1].

Does the Commission not consider there to be a potential conflict of interests involving President von der Leyen, who is already under investigation by the EPPO over the purchase of COVID-19 vaccines?’

According to Politico in Mar 2023;

‘It's as if Pfizer's massive COVID-19 vaccine deal with the European Commission were written with disappearing ink: the more time passes, the more details seem to vanish.

For a while now controversy has raged around the text messages supposedly exchanged between Commission President Ursula von der Leyen and Pfizer Chief Executive Albert Bourla in the run-up to the April 2021 deal for 1.1 billion doses of the BioNTech/Pfizer vaccine. The content and even existence of the messages has been shrouded in secrecy, with requests for clarification met with a fat "no comment."‘

Unelected war hawk Ursula VDL has financial links to Pfizer, Orgenesis, Israel, Vanguard and Blackrock (who were invited to the G7 and are buying up Ukraine as we speak).

Do they think we don’t see them?

🐒